Listed by the USPTO as RILEY, JEZIA
Tech Center 1600 • Art Units: 1637 1651 1681 1682
This examiner grants 83% of resolved cases
RILEY, JEZIA is a USPTO patent examiner in tech center 1600 and art unit 1637. The profile records 1323 resolved cases, an allowance rate of 83.0%, and a median of 895 days to allowance. The large resolved-case volume provides a strong basis for understanding the recorded prosecution pattern. The allowance rate indicates that allowance is common, while the median interval shows that matters generally require substantial examination time despite the favorable outcome measure.
The interview lift is 7.2%, reflecting a limited association between interviews and allowance outcomes. Illumina Inc., Nitto Boseki Co., Ltd., and Oxford Nanopore Technologies PLC are the listed leading companies. Crowell, WOLF GREENFIELD & SACKS, P.C., and AMSTER, ROTHSTEIN & EBENSTEIN LLP are the listed leading firms. Practitioners may prioritize precise written prosecution and use interviews selectively, while treating the 895-day median as a scheduling reference.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18561834 | METHODS FOR COMPLEMENT STRAND SEQUENCING | Non-Final OA | Oxford Nanopore Technologies PLC |
| 18488502 | MOLECULES COMPRISING BRANCHED LINKERS AND METHODS OF USE | Non-Final OA | 10x Genomics, Inc. |
| 18009111 | NUCLEIC ACID LIPID PARTICLE VACCINE | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 18687723 | HYBRIDIZATION PROBES CONTAINING FLUORINATED CARBON CHAINS AND RELATED METHODS | Non-Final OA | University of Utah Research Foundation |
| 18800335 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate |
| 18650800 | CONTROLLED POLYNUCLEOTIDE TRANSLOCATION IN NANOPORE SEQUENCING | Non-Final OA | ILLUMINA, INC. |
| 18393291 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | Non-Final OA | Illumina, Inc. |
| 18781157 | BISULFITE-FREE, BASE-RESOLUTION IDENTIFICATION OF CYTOSINE MODIFICATIONS | Non-Final OA | Ludwig Institute for Cancer Research Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy83.0% of resolved applications examined by Jezia Riley were allowed (1,323 resolved cases), compared with 45.4% across Art Unit 1637 over the last five years.
This examiner's interview lift is +7.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jezia Riley took 895 days on average from filing to allowance.
Jezia Riley examines applications in Art Unit 1637 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
